Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kosuke Imamura

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Frontiers in Immunology|April 17, 2026
A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancerYoshihiko Goto, Garry Dolton, Hannah Thomas, et al.
International Journal of Molecular Sciences|November 26, 2022
Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung CancerKosuke Imamura, Yusuke Tomita, Ryo Sato, et al.
Journal of Clinical Medicine|June 1, 2019
Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal AntibodiesRyo Sato, Kosuke Imamura, Shinya Sakata, et al.
Oncoimmunology|June 3, 2022
<i>Clostridium butyricum</i> therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitorsYusuke Tomita, Yoshihiko Goto, Shinya Sakata, et al.
Internal Medicine (Tokyo, Japan)|February 14, 2020
Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab TreatmentKei Nakashima, Koichi Saruwatari, Ryo Sato, et al.
Research Square|December 31, 2025
β-III tubulin identifies anti-fibrotic state of pericytes in pulmonary fibrosisYoh-Suke Mukouyama, Ryo Sato, Kosuke Imamura, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
β-III tubulin identifies anti-fibrotic state of pericytes in pulmonary fibrosisRyo Sato, Kosuke Imamura, Tatsuya Tsukui, et al.
Cancers|January 11, 2024
Association of <i>Clostridium butyricum</i> Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy CombinationsYusuke Tomita, Shinya Sakata, Kosuke Imamura, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Frontiers in Immunology|April 17, 2026
A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancerYoshihiko Goto, Garry Dolton, Hannah Thomas, et al.
International Journal of Molecular Sciences|November 26, 2022
Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung CancerKosuke Imamura, Yusuke Tomita, Ryo Sato, et al.
Journal of Clinical Medicine|June 1, 2019
Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal AntibodiesRyo Sato, Kosuke Imamura, Shinya Sakata, et al.
Oncoimmunology|June 3, 2022
<i>Clostridium butyricum</i> therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitorsYusuke Tomita, Yoshihiko Goto, Shinya Sakata, et al.
Internal Medicine (Tokyo, Japan)|February 14, 2020
Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab TreatmentKei Nakashima, Koichi Saruwatari, Ryo Sato, et al.
Research Square|December 31, 2025
β-III tubulin identifies anti-fibrotic state of pericytes in pulmonary fibrosisYoh-Suke Mukouyama, Ryo Sato, Kosuke Imamura, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
β-III tubulin identifies anti-fibrotic state of pericytes in pulmonary fibrosisRyo Sato, Kosuke Imamura, Tatsuya Tsukui, et al.
Cancers|January 11, 2024
Association of <i>Clostridium butyricum</i> Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy CombinationsYusuke Tomita, Shinya Sakata, Kosuke Imamura, et al.
Pageof 3